Extent of late gadolinium enhancement in cardiovascular magnetic resonance and its relation with left ventricular diastolic function in patients with hypertrophic cardiomyopathy

Circulation Journal

Volumn 72, Issue 9, 2008, Pages 1449-1453

  Choi, Dae Sik ^a   Ha, Jong Won ^a   Choi, Byoungwook ^a   Yang, Woo In ^a   Choi, Eui Young ^a   Rim, Se Joong ^a   Chung, Namsik ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Cardiovascular magnetic resonance; Diastolic function; Hypertrophic cardiomyopathy; Late gadolinium enhancement

Indexed keywords

GADOLINIUM;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD FLOW; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART VOLUME; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE ENHANCEMENT; MALE; MITRAL VALVE REGURGITATION; NUCLEAR MAGNETIC RESONANCE IMAGING; STATISTICAL SIGNIFICANCE;

ADULT; AGE FACTORS; AGED; CARDIOMYOPATHY, HYPERTROPHIC; DIASTOLE; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MITRAL VALVE; MITRAL VALVE INSUFFICIENCY; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 50449096089     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-07-0874     Document Type: Article

References (24)

1. Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H, et al. Hypertrophic cardiomyopathy: The importance of the site and the extent of hypertrophy (A review). Prog Cardiovasc Dis 1985; 28: 1-83.
2. Maron BJ. Hypertrophic cardiomyopathy. Lancet 1997; 350: 127-133.
3. Maron BJ. Hypertrophic cardiomyopathy: A systematic review. JAMA 2002; 287: 1308-1320.
4. Anderson KR, Sutton MG, Lie JT. Histopathological types of cardiac fibrosis in myocardial disease. J Pathol 1979; 128: 79-85.
5. St John Sutton MG, Lie JT, Anderson KR, O'Brien PC, Frye RL. Histopathological specificity of hypertrophic obstructive cardiomyopathy: Myocardial fibre disarray and myocardial fibrosis. Br Heart J 1980; 44: 433-443.
6. Nihoyannopoulos P, Karatasakis G, Frenneaux M, McKenna WJ, Oakley CM. Diastolic function in hypertrophic cardiomyopathy: Relation to exercise capacity. J Am Coll Cardiol 1992; 19: 536-540.
7. Pak PH, Maughan L, Baughman KL, Kass DA. Marked discordance between dynamic and passive diastolic pressure-volume relations in idiopathic hypertrophic cardiomyopathy. Circulation 1996; 94: 52-60.
8. Lombardi R, Betocchi S, Losi MA, Tocchetti CG, Aversa M, Miranda M, et al. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation 2003; 108: 1455-1460.
9. Becker AE. Cardiomyopathies with particular reference to the diagnostic relevance of endomyocardial biopsies. Wien Klin Wochenschr 1988; 100: 787-791.
10. Moon JC, Mogensen J, Elliott PM, Smith GC, Elkington AG, Prasad SK, et al. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart 2005; 91: 1036-1040.
11. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003; 41: 1561-1567.
12. Choudhury L, Mahrholdt H, Wagner A, Choi KM, Elliott MD, Klocke FJ, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 40: 2156-2164.
13. Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 43: 2260-2264.
14. Teraoka K, Hirano M, Ookubo H, Sasaki K, Katsuyama H, Amino M, et al. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging 2004; 22: 155-161 (Erratum in: Magn Reson Imaging 2004; 22: 901).
15. Quinones MA, Waggoner AD, Reduto LA, Nelson JG, Young JB, Winters WL Jr, et al. A new, simplified and accurate method for determining ejection fraction with two-dimensional echocardiography. Circulation 1981; 64: 744-753.
16. Sanderson JE, Traill TA, Sutton MG, Brown DJ, Gibson DG, Goodwin JF. LV relaxation and filling in hypertrophic cardiomyopathy: An echocardiographic study. Br Heart J 1978; 40: 596-601.
17. Spirito P, Maron BJ. Relation between extent of LV hypertrophy and diastolic filling abnormalities in hypertrophic cardiomyopathy. J Am Coll Cardiol 1990; 15: 808-813.
18. Ommen SR, Nishimura RA. Hypertrophic cardiomyopathy. Curr Probl Cardiol 2004; 29: 239-291.
19. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of LV chamber stiffness in hypertensive patients. Circulation 2002; 105: 2512-2517.
20. Kim RJ, Judd RM. Gadolinium-enhanced magnetic resonance imaging in hypertrophic cardiomyopathy: In vivo imaging of the pathologic substrate for premature cardiac death? J Am Coll Cardiol 2003; 41: 1568-1572.
21. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of LV diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol 2002; 90: 1284-1289.
22. Sachdev V, Shizukuda Y, Brenneman CL, Birdsall CW, Waclawiw MA, Arai AE, et al. Left atrial volumetric remodeling is predictive of functional capacity in nonobstructive hypertrophic cardiomyopathy. Am Heart J 2005; 149: 730-736.
23. Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001; 103: 789-791.
24. Araujo AQ, Arteaga E, Ianni BM, Buck PC, Rabello R, Mady C. Effect of losartan on LV diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am J Cardiol 2005; 96: 1563-1567.